TY - JOUR
T1 - Plasma symmetric dimethylarginine reference limits from the Framingham offspring cohort
AU - Schwedhelm, Edzard
AU - Xanthakis, Vanessa
AU - Maas, Renke
AU - Sullivan, Lisa M.
AU - Atzler, Dorothee
AU - Lüneburg, Nicole
AU - Glazer, Nicole L.
AU - Riederer, Ulrich
AU - Vasan, Ramachandran S.
AU - Böger, Rainer H.
N1 - Funding Information:
This work was supported by the National Heart, Lung and Blood Institute’s Framingham Heart Study (Contract No. N01-HC-25195) and by a grant from the Deutsche Forschungsgemeinschaft (DFG-Bo 1431/4-1).
PY - 2011/11/1
Y1 - 2011/11/1
N2 - Background: Symmetric dimethylarginine (SDMA) is a by-product of protein methylation. Once released from proteins, SDMA is eliminated by the kidneys; consequently, plasma concentration has been suggested as a sensitive marker of renal function. Furthermore, recent work implicates SDMA in the pathogenesis of cardiovascular disease. To date, reference limits for SDMA plasma concentrations in healthy individuals are lacking. Methods: This study defined reference limits for plasma SDMA concentrations in 840 relatively healthy individuals of the Offspring Cohort from Framingham Heart Study (mean age 56 years, 61% women). Plasma SDMA concentrations were determined by LC-MS/MS using a stable isotope dilution assay. Results: The median SDMA concentration in the reference sample was 0.37 μmol/L (Q1, Q3:0.32, 0.43 μmol/L) and the reference limits were 0.225 and 0.533 (2.5th and 97.5th percentile). In a multivariable regression model, serum creatinine, age and total homocysteine were positively associated with SDMA (p<0.001 for all), whereas the body mass index and diastolic blood pressure were inversely related to SDMA (p-values<0.01 and 0.03, respectively). Conclusions: This study reports plasma SDMA reference limits from the community-based Framingham Heart Study. Plasma SDMA concentration was related positively to advancing age, but inversely to renal function. These reference limits may allow the identification of individuals with raised plasma SDMA concentrations.
AB - Background: Symmetric dimethylarginine (SDMA) is a by-product of protein methylation. Once released from proteins, SDMA is eliminated by the kidneys; consequently, plasma concentration has been suggested as a sensitive marker of renal function. Furthermore, recent work implicates SDMA in the pathogenesis of cardiovascular disease. To date, reference limits for SDMA plasma concentrations in healthy individuals are lacking. Methods: This study defined reference limits for plasma SDMA concentrations in 840 relatively healthy individuals of the Offspring Cohort from Framingham Heart Study (mean age 56 years, 61% women). Plasma SDMA concentrations were determined by LC-MS/MS using a stable isotope dilution assay. Results: The median SDMA concentration in the reference sample was 0.37 μmol/L (Q1, Q3:0.32, 0.43 μmol/L) and the reference limits were 0.225 and 0.533 (2.5th and 97.5th percentile). In a multivariable regression model, serum creatinine, age and total homocysteine were positively associated with SDMA (p<0.001 for all), whereas the body mass index and diastolic blood pressure were inversely related to SDMA (p-values<0.01 and 0.03, respectively). Conclusions: This study reports plasma SDMA reference limits from the community-based Framingham Heart Study. Plasma SDMA concentration was related positively to advancing age, but inversely to renal function. These reference limits may allow the identification of individuals with raised plasma SDMA concentrations.
KW - Framingham Heart Study
KW - LC-MS/MS
KW - Symmetric dimethylarginine
UR - http://www.scopus.com/inward/record.url?scp=80755171198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80755171198&partnerID=8YFLogxK
U2 - 10.1515/CCLM.2011.679
DO - 10.1515/CCLM.2011.679
M3 - Article
C2 - 21864208
AN - SCOPUS:80755171198
SN - 1434-6621
VL - 49
SP - 1907
EP - 1910
JO - Clinical Chemistry and Laboratory Medicine
JF - Clinical Chemistry and Laboratory Medicine
IS - 11
ER -